Sanofi Q2 Results Show Strong Growth, Upbeat 2024 Outlook
Company Announcements

Sanofi Q2 Results Show Strong Growth, Upbeat 2024 Outlook

Sanofi (SNY) has released an update.

Sanofi reports robust Q2 2024 sales growth of 10%, with high-performing Dupixent sales and successful pharma launches, despite a dip in vaccine sales compared to 2023. The company also proudly announces regulatory approvals for several drugs and an upgraded business EPS guidance for 2024, signaling stable growth prospects. These achievements underscore Sanofi’s strategic push towards becoming a leading AI-powered biopharmaceutical entity.

For further insights into SNY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySanofi price target raised to EUR 130 from EUR 125 at Citi
TheFlySanofi shipping BEYFORTUS 50mg, 100mg injection doses in U.S.
TipRanks Auto-Generated NewsdeskSanofi’s Dupixent Shows Promise for Skin Disease
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App